Onkologie. 2023:17(5):323-328 | DOI: 10.36290/xon.2023.061
Fixed duration therapy in patients with chronic lymphocytic leukemia
- Hemato-onkologické oddělení, FN Plzeň
The availability of targeted molecules such as anti-apoptotic bcl-2 protein (BCL2i) or Bruton's tyrosine kinase (BTKi) inhibitors has revolutionized the treatment of chronic lymphocytic leukemia (CLL). Clinical studies have demonstrated the efficacy and safety of these molecules in the treatment of both newly diagnosed and relapsing/refractory disease. A number of treatment regimens are available that are based on either continuous long-term BTKi monotherapy or fixed duration treatment combining venetoclax with another drug. Some of the advantages offered by the fixed duration therapy are discussed in the context of deciding on the appropriate therapy for a specific patient.
Keywords: chronic lymphocytic leukemia, fixed duration therapy, venetoclax, ibrutinib, acalabrutinib, BCL2i, BTKi, minimal residual disease.
Accepted: November 28, 2023; Published: November 29, 2023 Show citation
References
- Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311e22.
Go to original source... 
Go to PubMed... - Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107e20. Go to original source... Go to PubMed...
- Kater AP, Harrup R, Kipps TJ , et al. Final 7-year follow up and retreatment substudy analysis of MURANO: venetoclax - rituximab (VENR) - treated patients with relapsed/refraktory chronic lymphocytic leukemia (R/R CLL). EHA 2023, abstract S201. Go to original source...
- Seymour JF, Kipps TJ, Eichhorst BF, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140(8):839-850. Go to original source... Go to PubMed...
- Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380(23):2225e36. Go to original source... Go to PubMed...
- Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax- obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. EHA 2023, abstrakt S145. Go to original source...
- Eichhorst B, Niemann CU, Kater AP, et al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. N Engl J Med. 2023;388(19):1739-1754. Go to original source... Go to PubMed...
- Tam CS, Allan JN, Siddiqi T, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139(22):3278-3289. Go to original source... Go to PubMed...
- Kater AP, Owen C, Moreno C. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. NEJM Evid. 2022;1(7). doi: 10.1056/EVIDoa2200006. Go to original source... Go to PubMed...
- Thompson MC, Harrup RA, Coombs CC, et al. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv. 2022;6(15):4553-4557. Go to original source... Go to PubMed...
- Kater AP, Seymour JF, Hillmen P, et al. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2019;37:269-277. Go to original source... Go to PubMed...
- Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology. 2020;21(9):1188-1200. Go to original source... Go to PubMed...
- Davids MS, Lampson BL, Tyekucheva S, et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021;22(10):1391-1402. Go to original source... Go to PubMed...
- Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol. 2022;196(4):947-953. Go to original source... Go to PubMed...
- Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia With TP53 alterations. N Engl J Med. 2020;383(5):498-500. Go to original source... Go to PubMed...
- Byrd JC, Woyach JA, Furman RR, et al. Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with > 6 Years of Follow-up. Blood. 2022; 40(Supplement 1):9865-9867. Go to original source...
- Al-Sawaf O, Zhang C, Lu T, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow- up from the randomized CLL14 study. J Clin Oncol. 2021;39(36):4049-4060. Go to original source... Go to PubMed...
- Fürstenau M, Thus YJ, Robrecht S, et al. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. Blood. 2023;142(5):446-459. Go to original source... Go to PubMed...
- Lampson BL, Brown JR. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol. 2018;11(3):185-194. Go to original source... Go to PubMed...
- Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129(11):1469-1479. Go to original source... Go to PubMed...
- Blombery P, Anderson MA, Gong J, et al. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discov. 2019;9(3):342-353. Go to original source... Go to PubMed...
- Tausch E, Schneider C, Yosifov D, et al. Genetic markers and outcome in front line obinutuzumab plus chlorambucil or venetoclax - updated analysis of the CLL14 trial. EHA 2021, abstrakt S144. Go to original source...
- Woyach JA, Ruppert AS, Guinn D et al. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017;35(13):1437-1443. Go to original source... Go to PubMed...
- Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787-798. Go to original source... Go to PubMed...
- Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Advances. 2013;3(12):1799-1807. Go to original source... Go to PubMed...
- Roeker LE, Han Y, Ryan KJ, et al. Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Blood. 2022;140 (Supplement 1):7025-7027. Go to original source...